Verona Pharma Plc (VRNA)

[Amatuer17]

https://seekingalpha.com/article/4594258-verona-pharma-ensifentrine-vs-dupixent-ensifentrine-is-a-breath-of-fresh-air

Firstly, in the Phase 3 ENHANCE-1 and ENHANCE-2 trials, ensifentrine reported a 36% and 42% pbo-adjusted reduction in COPD exacerbation at week 24, respectively. In contrast, dupixent demonstrated a 30% pbo-adjusted reduction in COPD exacerbation at week 52 in the BOREAS trial.

Verona Pharma is expected to submit an NDA by 1H 2023, PDUFA by 1H 2024, and launch in the US by 2H 2024.